文献速递浆细胞疾病

伊沙佐米、来那度胺和地塞米松治疗新诊断多发性骨髓瘤:含伊沙佐米维持治疗的长期随访

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
PubMed 文献 · Leukemia · 2019-01-29

该研究评估全口服方案每周伊沙佐米联合来那度胺-地塞米松(IRd)诱导后单药伊沙佐米维持治疗新诊断多发性骨髓瘤的长期疗效与安全性。65例入组,53例接受诱导,42例未行移植者总缓解率80%,中位随访56个月,总人群中位无进展生存期35.4个月;25例接受维持治疗者中8例缓解加深,该亚组中位无进展生存期37.2个月。

要点

  • 每周IRd诱导后伊沙佐米维持治疗具有高活性和可接受的毒性。
  • 未行移植患者总缓解率80%,≥非常好的部分缓解率63%,完全缓解率32%。
  • 总人群中位无进展生存期35.4个月,维持治疗亚组为37.2个月。

核心结论

  • 每周IRd方案序贯伊沙佐米维持治疗具有高活性且毒性可接受,可长期给药且无累积毒性证据。

研究设计与样本

  • 研究纳入65例新诊断多发性骨髓瘤患者,其中53例接受每周伊沙佐米4 mg(第1、8、15天)联合来那度胺25 mg(第1-21天)和地塞米松40 mg(第1、8、15、22天)治疗,最多十二个28天诱导周期。

主要发现

  • 23例因干细胞移植中止诱导,其余42例中总缓解率80%,包括≥非常好的部分缓解率63%和完全缓解率32%。
  • 中位随访56个月时,总人群中位无进展生存期为35.4个月。
  • 25例接受伊沙佐米维持治疗,其中8例缓解加深(≥非常好的部分缓解率76%),该亚组中位无进展生存期为37.2个月。
  • 42例未行干细胞移植患者中9例(占总人群14%)因不良事件需要中止治疗。
  • 治疗期间伊沙佐米中位相对剂量强度≥96%,来那度胺中位相对剂量强度为88-94%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy and safety of the all-oral combination of weekly ixazomib plus lenalidomide-dexamethasone (IRd), followed by single-agent ixazomib maintenance in NDMM patients. Of 65 enrolled patients, 53 received ixazomib 4 mg (days 1, 8, and 15) plus lenalidomide 25 mg (days 1-21) and dexamethasone 40 mg (days 1, 8, 15, and 22) for up to twelve 28-day induction cycles. Twenty-three patients discontinued induction for stem cell transplantation (SCT). In the remaining 42 patients, overall response rate was 80%, including 63% ≥very good partial response (VGPR) and 32% complete responses. At a median follow-up of 56 months, median progression-free survival (PFS) was 35.4 months in the total population. Twenty-five patients received ixazomib maintenance; eight deepened their response (76% ≥VGPR), and median PFS was 37.2 months in this subgroup. Nine of 42 patients who did not proceed to SCT (14% of total population) had an adverse event requiring discontinuation. Ixazomib (median ≥ 96%) and lenalidomide (median 88-94%) relative dose intensities were maintained throughout treatment. Weekly IRd, followed by ixazomib maintenance, was highly active with acceptable toxicity, enabling long-term administration with no evidence of cumulative toxicities.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kumar SK, Berdeja JG, Niesvizky R, et al. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019. PMID: 30696949. doi:10.1038/s41375-019-0384-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。